. Author manuscript; available in PMC: 2014 Dec 11.

Published in final edited form as: Hepatology. 2014 Apr 25;59(6):2321–2330. doi: 10.1002/hep.26925

Table 1.

Preclinical study morphometric measurements, plasma biochemical analysis, and hepatic isoprostane content analysis.

	Body mass (g)	Liver mass (g)	ALT (U/L)	AST (U/L)	Alk phos (U/L)	Hepatic isoprostane content (ng/g)
	Body mass (g)	Liver mass (g)	ALT (U/L)	AST (U/L)	Alk phos (U/L)	F₂-III	F₂-IV	F₂-VI
Control	220 ± 33	10.8 ± 0.8	49 ± 8	71 ± 6	290 ± 17	1.4 ± 0.3	0.06 ± 0.19	1.7 ± 0.2
CCl₄	243 ± 27	11.6 ± 0.8	378 ± 84	950 ± 378	281 ± 27	46.7 ± 10.9	0.90 ± 0.19	36.4 ± 3.2
HFHC diet	527 ± 67	17.0 ± 3.1	74 ± 34	200 ± 140	136 ± 43	20.2 ± 2.8	0.60 ± 0.14	5.7 ± 1.3